In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns

This article is powered by The Rose Sheet

Executive Summary

Marketers' websites and product labels stated other noncompliant claims that render their products unapproved new drugs, but references to opioid withdrawal treatment got FDA Commissioner Scott Gottlieb's attention. "Despite our warnings and previous regulatory and enforcement actions, we continue to find marketers actively selling kratom with unsubstantiated claims," Gottlieb says.

Advertisement

Related Content

Opioid Treatment Claims Linked To Depression Drug Found In Supplements
Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales
FDA's Opioid Label For Kratom Called Misbranding By Marketers

Topics

Advertisement
UsernamePublicRestriction

Register

RS121822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel